Advanced search
Publication Cover
Modern Rheumatology Volume 23, 2013 - Issue 2
Journal homepage
129
Views
11
CrossRef citations to date
0
Altmetric
Original Article

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

Akito TakamuraDepartment of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
,
Shintaro HirataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Japan, Kitakyushu, Japan
,
Hayato NagasawaDepartment of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
Hideto KamedaDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Yohei SetoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Tatsuya AtsumiDepartment of Internal Medicine II, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
,
Makoto DohiDepartment of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
,
Takao KoikeSapporo Medical Center NTT EC, Sapporo, Hokkaido, Japan
,
Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
&
Masayoshi HarigaiDepartment of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;Global Center of Excellence Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, JapanCorrespondence[email protected]
 show all
Pages 297-303 | Received 16 Jan 2012, Accepted 19 Apr 2012, Published online: 02 Jan 2014

REFERENCES

  • Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
  • Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
  • Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheu-matoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol Japan Rheum Assoc. 2011.
  • Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70:2148–51.
  • Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8.
  • Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor mono-clonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19:351–7.
  • Japan College of Rheumatology. Guideline for the use of TNF inhibitors in rheumatoid arthritis, Japan College of Rheumatol-ogy. Tokyo 2010 (in Japanese). http://www.ryumachi-jp.com/ info/guideline_TNF_100930.html (updated 30-09-2010; cited 01-11–2011).
  • Japan College of Rheumatology. Guideline for the use toc-ilizumab in rheumatoid arthritis, Japan College of Rheumatology (in Japanese). 2010. http://www.ryumachi-jp.com/info/guideline_ TCZ_100716.html (updated 16-07–2010).
  • Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third Inter-national Workshop on Lung Tumor and Differentiation Antigens:overview of the results of the central data analysis. Int J Cancer Suppl. 1994;8:6–26.
  • Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637–42.
  • Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med. 2002;41:467–73.
  • Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27:1164–70.
  • Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48:195–202.
  • Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58:872–5.
  • Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneu-mocystis pneumonia. Chest. 2007;131:1173–80.
  • Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to inf-liximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol Japan Rheum Assoc. 2009;19:478–87.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
  • Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis-a report from the ad-hoc committee for safety of biological DAMRDs of the Japan College of Rheumatology. 2012 (submitted).
  • van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum bio-markers in idiopathic pulmonary fibrosis. Pulm Pharmacol 'Ther. 2010;23:515–20.
  • Oyama T, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Oyama H, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung. 1997;175:379–85.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.